BIOMAT Database Logo BIOMAT Database Logo

The treatment with L-dopa and amantadine in Parkinson's disease. 1975

G Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprisan, and M Merling, and E Nemteanu, and M Ciunru, and I Koropitzer

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000547 Amantadine An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. 1-Aminoadamantane,Adamantylamine,Adekin,Aman,Amanta,Amanta-HCI-AZU,Amanta-Sulfate-AZU,Amantadin AL,Amantadin AZU,Amantadin Stada,Amantadin-neuraxpharm,Amantadin-ratiopharm,Amantadina Juventus,Amantadina Llorente,Amantadine Hydrochloride,Amantadine Sulfate,Amixx,Cerebramed,Endantadine,Gen-Amantadine,Infecto-Flu,Infex,Mantadix,Midantan,PMS-Amantadine,Symadine,Symmetrel,Viregyt,Wiregyt,tregor,1 Aminoadamantane,AL, Amantadin,AZU, Amantadin,Amanta HCI AZU,Amanta Sulfate AZU,AmantaHCIAZU,AmantaSulfateAZU,Amantadin neuraxpharm,Amantadin ratiopharm,Amantadinneuraxpharm,Amantadinratiopharm,Gen Amantadine,GenAmantadine,Hydrochloride, Amantadine,Infecto Flu,InfectoFlu,Juventus, Amantadina,Llorente, Amantadina,PMS Amantadine,PMSAmantadine,Stada, Amantadin,Sulfate, Amantadine

Related Publications

G Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprisan, and M Merling, and E Nemteanu, and M Ciunru, and I Koropitzer
Treatment of Parkinson's disease with amantadine and L-Dopa.
January 1972, European neurology,
G Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprisan, and M Merling, and E Nemteanu, and M Ciunru, and I Koropitzer
[Prolonged treatment of Parkinson's disease with amantadine and L-Dopa].
October 1971, Minerva medica,
G Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprisan, and M Merling, and E Nemteanu, and M Ciunru, and I Koropitzer
Combined treatment of Parkinson's disease with amantadine and L-dopa.
June 1970, Lancet (London, England),
G Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprisan, and M Merling, and E Nemteanu, and M Ciunru, and I Koropitzer
L-dopa and amantadine hydrochloride in Parkinson's disease.
April 1971, Internationale Zeitschrift fur klinische Pharmakologie, Therapie, und Toxikologie. International journal of clinical pharmacology, therapy, and toxicology,
G Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprisan, and M Merling, and E Nemteanu, and M Ciunru, and I Koropitzer
[Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease].
January 1974, Medicinski arhiv,
G Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprisan, and M Merling, and E Nemteanu, and M Ciunru, and I Koropitzer
[Results of two new drugs in Parkinson's disease: L-dopa and amantadine].
February 1970, Revue neurologique,
G Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprisan, and M Merling, and E Nemteanu, and M Ciunru, and I Koropitzer
[Treatment of Parkinson's syndrome with L-dopa associated with diphenhydramine hydrochloride and amantadine hydrochloride].
January 1970, Sistema nervoso,
G Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprisan, and M Merling, and E Nemteanu, and M Ciunru, and I Koropitzer
L-dopa treatment and Parkinson's disease.
June 1986, The Quarterly journal of medicine,
G Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprisan, and M Merling, and E Nemteanu, and M Ciunru, and I Koropitzer
[Treatment of Parkinson's disease with L-dopa].
May 1970, La Clinica terapeutica,
G Pendefunda, and B Pollingher, and F Stefanache, and A Gavril, and C Oprisan, and M Merling, and E Nemteanu, and M Ciunru, and I Koropitzer
L-Dopa treatment in Parkinson's Disease.
January 1970, European neurology,
Copied contents to your clipboard!